Verici Dx (LSE:VRCI) has achieved status as an Olink Certified Service Provider, part of Thermo Fisher's Life Sciences Solutions.
The AIM-listed company develops advanced clinical diagnostics for organ transplant patients, with its lead product Tutivia targeting early detection of acute rejection after kidney transplant.
The certification lets Verici Dx run Olink-based proteomics assays at its CAP-certified and CLIA-accredited laboratory, covering biomarker discovery, algorithm development, validation and clinical use.
The company will use the platform both for client work and to advance its own protein biomarker pipeline.
Certification requires organisations to complete rigorous training and annual concordance testing, and Verici Dx says its offering goes beyond standard sample analysis, combining bioinformatics, a CAP/CLIA/ISO-compliant quality framework and multi-omics expertise across genomics, transcriptomics and proteomics.
The company has already applied the capability in a project for a major pharmaceutical company, analysing samples from a GLP-1 clinical trial using a custom proteomic panel, with results feeding into ongoing scientific analyses and data submissions.
3333333, adding that the company aims to "help organizations generate more meaningful biological insights and translate complex data into clinically relevant applications."
News Intelligence what this means for the company
Verici Dx has secured Olink Certified Service Provider status, enabling it to run proteomics assays at its CAP/CLIA-accredited lab for both client work and its own biomarker pipeline. The company has already deployed the capability in a GLP-1 trial project for a pharma client. This adds a revenue stream alongside Tutivia, which generated $2.9m in 2025 against total revenues of $3.7m, but the announcement contains no financial guidance, customer commitments, or timeline for material revenue contribution from the new service line.
The certification expands Verici Dx's addressable market and diversifies revenue beyond its core transplant diagnostics pipeline, but without disclosed contract value, customer pipeline, or ramp expectations, the near-term financial impact remains opaque. The company remains loss-making on an adjusted EBITDA basis ($6.2m loss in 2025), so the timing and scale of service revenue will be critical to trajectory.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
